-

Simulations Plus Sets Date for Third Quarter Fiscal Year 2021 Earnings Release and Conference Call

Conference call to be on Monday, July 12, 2021, at 4:15 p.m. ET

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its financial results for the third quarter of fiscal year 2021, the period ended May 31, 2021, after the close of the financial markets on Monday, July 12, 2021.

The Company will host a conference call on July 12, 2021, at 4:15 p.m. Eastern Time. All interested parties are invited to join the call by registering here or by calling 1-201-389-0879. Please join five to 10 minutes before the scheduled start time. The call will be simulcast live on the Internet, and the webcast will be available on the Investors page of the Simulations Plus website under Conference Calls & Presentations. A replay of the webcast will be available on the website approximately one hour following the call.

About Simulations Plus, Inc.

Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | Read our Environmental, Social, and Governance (ESG) Report.

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
(661) 723-7723
renee@simulations-plus.com

Hayden IR
Mr. Brian S. Siegel, IRC®, M.B.A.
(346) 396-8696
slp@haydenir.com

Simulations Plus, Inc.

NASDAQ:SLP

Release Summary
Simulations Plus announced today that it will report its 3rd quarter fiscal year 2021 results on Monday, July 12, 2021, with a webcast at 1:15 pm ET.
Release Versions

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
(661) 723-7723
renee@simulations-plus.com

Hayden IR
Mr. Brian S. Siegel, IRC®, M.B.A.
(346) 396-8696
slp@haydenir.com

Social Media Profiles
More News From Simulations Plus, Inc.

Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that helps advance biopharma innovation, today announced it is building the agentic layer of Composer, its AI-native platform for model-informed drug development, using the NVIDIA BioNeMo Agent Toolkit. The initiative expands the companies’ collaboration announced in May 2026, extending their work in GPU-...

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle. The collaboration brings together Simu...

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded research collaboration with Lonza Group AG (“Lonza”), a leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry, and the U.S. Food and Drug Administration (FDA) to develop and validate a me...
Back to Newsroom